Bj. Gertz et al., MONITORING BONE-RESORPTION IN EARLY POSTMENOPAUSAL WOMEN BY AN IMMUNOASSAY FOR CROSS-LINKED COLLAGEN PEPTIDES IN URINE, Journal of bone and mineral research, 9(2), 1994, pp. 135-142
A new immunoassay using an ELISA approach for measuring urinary excret
ion of cross-linked N-telopeptides of type 1 collagen was evaluated as
a specific measure of bone resorption. The assay was applied to 65 ea
rly postmenopausal women who participated in a placebo-controlled tria
l of the aminobisphosphonate, alendronate sodium. Eight blood and urin
e samples were collected over a 9 month interval. Baseline crosslinked
peptide excretion varied from 26 to 216 pmol BCE (bone collagen equiv
alents)/mu mol Cr. Within-subject variability (CV) for cross-linked pe
ptide excretion was 20.2% over the 9 months in placebo-treated subject
s, substantially less than that observed for other biochemical markers
of bone resorption: 45, 53, and 63% for fasting urinary calcium and h
ydroxyproline and 24 h urinary lysylpyridinoline (HPLC assay), respect
ively. Baseline cross-linked peptide excretion correlated significantl
y (p < 0.001) with baseline total urine lysylpyridinoline and serum os
teocalcin, but not with the other biochemical markers. Initial peptide
excretion also correlated inversely with lumbar spine bone mineral de
nsity at entry (r = -0.26, p < 0.05). Treatment for 6 weeks with alend
ronate produced a dose-dependent suppression of cross-linked peptide e
xcretion (0 +/- 8, 29 +/- 6, 56 +/- 5, and 64 +/- 3% for 0, 5, 20, and
40 mg, respectively, p < 0.01 versus placebo for treatment effect), w
ith a return toward pretreatment values during follow-up. Measurement
of the urinary cross-linked N-telopeptides of type I collagen by this
new ELISA approach appears promising as a simple and reliable method t
o assess overall bone resorption. It may prove especially useful in mo
nitoring the treatment of osteoporotic women with antiresorptive thera
py. Its utility in identifying those women in the high resorption rang
e at menopause who may be at greater risk for osteoporosis should also
be assessed in future studies.